Blog
Drawing the Best Results from Blood Biopsies
We’ve come a long way since tissue biopsies were considered the go-to way to obtain samples needed to test for cancer. Breast cancer, prostate cancer, and lung cancer all required invasive methods to obtain tissue. Thankfully, liquid biopsies--whether through samples...
The Power of Microbiome Integration to Multiomics in Early Cancer Detection: Guest blog from our CSO – Eddie Adams, Ph.D.
The OncobiotaLUNGdetect is a multi-species, multi-omic liquid biopsy assay that will aid clinicians in risk stratification of pulmonary nodules. Micronoma is the first company to commercialize an assay that integrates metagenomic, proteomic, clinical and radiomic...
Team Spotlight: Jerry Lee, Senior Scientist- Bioinformatician
Jerry started working for Micronoma in May 2023. He was born in China, and raised in San Francisco, where he also went to college (California State, East Bay). As a Senior Scientist, Jerry is part of the computational biology team responsible for data analysis and...
Micronoma Teams Up with NYU Grossman School of Medicine on Lung Cancer Research Grant Utilizing Microbial Biomarkers
This latest collaboration seeks synergistic methodologies that will enable the earliest, best predictions of lung cancer May 18, 2023. SAN DIEGO, Calif.-- Micronoma announced today that it is serving as the industry partner on a grant the NYU Grossman School of...
Team Spotlight: Nick Grigoriev, Customer Care Manager
Nick started working for Micronoma in February 2023. He was born and raised in San Diego, and went to college at UC Davis. As a Customer Care Manager, Nick’s main goal is to create a white glove customer experience at Micronoma. He is responsible for building our...
Incidental Detection of Lung Cancer: Can We Be More Proactive?
Up to two million incidentally detected pulmonary nodules (IPN) appear each year onimages coming from diagnostic scans that patients undergo for reasons unrelated tolung cancer. These nodules are abnormal growths (neoplasms) that form in the lungand, upon...
Guest CEO blog from Sandrine Miller-Montgomery:
Precision or Personalized Medicine – Is it Tomato or Tomahto?
At Micronoma we are putting everything we have into ensuring that development of diagnostics like our Oncobiota™ platform will be a key propellent for creating new opportunities in precision medicine by identifying cancer at its earliest stages. But first, a quick...
Team Spotlight: Mauka Manuwai, Research Associate II
Mauka Manuwai joined the Micronoma team in July 2022 as a Research Associate II. Originally from Medford, Oregon, he decided to trade the evergreen trees for the salty waves and sandy beaches of San Diego in 2021. In Hawaiian, his name Mauka means: Towards the...
New Research Puts Fungi in Cancer Diagnosis Spotlight
Our recent collaboration with the Weizmann Institute of Science and the University of California San Diego found that fungi are ubiquitous in human cancer types and often interact with bacteria in synergistic, rather than competitive ways. This is the latest chapter...
Team Spotlight: Todd Czerwinski, Vice President of Business Development
Todd Czerwinski joined the Micronoma team formally in May of 2022 as the Vice President of Business Development. Originally from the suburbs of Detroit, he has been in San Diego since the summer of 1995 (he wants us to know it was early September '95 - officially...
Micronoma Keeps Science in the Driver’s Seat through Testing Economic Times
At Micronoma, we turn to science first to guide us down the road to delivering the first diagnostic platform technology using the microbiome to detect early-stage cancer. At the same time, we keep a watchful eye on our resources so we can steer clear of the...
Team Spotlight: Celia Sepulveda, Corporate Communications Director
Celia Sepulveda joined Micronoma formally in April of 2022 as the Corporate Communications Director, though she has been working with Micronoma as a consultant from the announced launch in fall of 2020. Born in Santa Rosa, California and raised in New Jersey, she has...
Team Spotlight: Andrew Lin CLS (Clinical Laboratory Scientist) Supervisor
Andrew Lin joined Micronoma in July 2021 as a CLS Supervisor and is responsible for building, operating, and managing a clinical lab that is compliant with all CLIA/CAP/NY regulations. Though originally from Yorba Linda, Ca, he has lived in San Diego for the last four...
The Economic Case for Targeted Early Cancer Detection
As we pave the way for better patient outcomes with the first minimally invasive microbiome-driven liquid biopsy technology, we also want to make sure that the important economic benefits that health insurance companies will reap from covering early cancer detection...
Team Spotlight: Stephen Wandro, Senior Scientist, Computational Biology
Stephen Wandro joined Micronoma in August 2020 as a senior scientist, with a speciality in analyzing DNA sequencing data. He is responsible for building computational pipelines and interpreting biological data with statistics and machine learning. He organizes and...
Micronoma Puts Machine Learning to Work
It’s no exaggeration to say the development of Micronoma’s Oncobiota™ microbiome-driven liquid-biopsy technology to detect cancer at an early stage would not be possible without extensive expertise and use of machine learning (ML) tools. Micronoma’s proprietary...
Team Spotlight: Chuck Tripp, Quality Manager
Chuck Rosales joined Micronoma in July 2021 as the quality manager, responsible for implementing and maintaining all compliance and quality procedures to ensure that patient testing is performed with the highest standards. Though born in Kansas, he has lived in San...
Why is Clonal Evolution Still a Sterile Theory?
Despite major revelations in the science of cancer, a classic theory of how it develops—clonal evolution—has remained a perplexing vestige of ‘sterile’ cancer biology. Arguing against the sterility of tumors, the last decade of research has revealed metabolically...
Hallmarks of Cancer Update Sharpens Focus on Micronoma’s Work
Inclusion of microbiome supports Micronoma’s efforts to improve cancer detection The “hallmarks of cancer” have captured the core features of cancer biology and served as a guide for future research since their original publication in Cell in 2000. Since then, the...
Team Spotlight: Gabriella Fanelli
Gabriella Fanelli, Executive Assistant Gabriella joined Micronoma in the Spring of 2021. Gabriella makes everything at Micronoma run smoothly and efficiently. As the only person on the team who’s not science-focused - she was an English literature major in college -...
Team Spotlight: Akanksha Singh-Taylor
Akanksha Singh-Taylor, Senior Scientist Akanksha Singh-Taylor joined Micronoma in September 2021 as a senior scientist on our wet lab side. Originally from Delhi, India, Akanksha moved to Houston when she was 10. During her work with children and adults with severe...
Cleaning Up Contamination Misconceptions
While researchers have typically seen microbes only as contaminants and discarded them, Micronoma has set itself apart by seeing the treasure trove of opportunity microbes represent to detect and identify cancer early. Using liquid biopsy–a simple blood draw–Micronoma...
Team Spotlight: Darryl Garrison
Darryl Garrison, Chief Operating Officer Meet Darryl, our Chief Operating Officer. Darryl has more than 20 years of experience in the molecular diagnostic industry. He has been involved in setting up and running molecular clinical laboratories and has been responsible...
Team Spotlight: Serena Fraraccio
Serena Fraraccio, Senior Scientist Serena Fraraccio’s road to becoming Micronoma’s first wet lab senior scientist started in her hometown in Isernia, Italy, where an interest in the environment and biology blossomed into a career that has gone from winters in Alaska...
Advances Push Cancer Research from Human-Centric to Microbiome-Focused
The recent realization that the microbiome impacts human health and disease states, as well as the rapid evolution of research tools has led to an exciting and critical juncture, when we can now go deeper than ever in understanding and using microbiome science for...
Website Terms of Use, Privacy Policy, and Licenses and Accreditations
Micronoma, INC., CLIA #05D2253538
Oncobiota™ LDT is under development and is currently not available for commercial use in any jurisdiction. Once available under CLIA license, Oncobiota™ will be available in the United States by prescription only.
Contact Us
If you have questions or would like to learn more, please email us at info@micronoma.com or learn about joining our team at Careers.
Micronoma
6342 Ferris Square
San Diego, CA 92121